COL4A Disorders and HNF1B Disorders
COL4A disorders are genetic multisystem diseases caused by mutations in collagen type IV genes (COL4A1-COL4A6) that primarily affect basement membranes throughout the body, while HNF1B disorders are caused by mutations or deletions in the hepatocyte nuclear factor-1β gene, resulting in a syndrome characterized by kidney disease, diabetes (MODY5), and multiple organ involvement.
COL4A Disorders
What They Are
COL4A disorders result from mutations in genes encoding type IV collagen chains, which are essential structural components of basement membranes in blood vessels, kidneys, eyes, and other tissues 1. The six COL4A genes (COL4A1-COL4A6) encode α-chains that assemble into three heterotrimers providing structural support and signaling functions 1.
Clinical Manifestations
Gould Syndrome (COL4A1/COL4A2 mutations):
- Cerebrovascular disease: Porencephaly, small-vessel disease, leukoencephalopathy, intracerebral hemorrhage, and intracranial aneurysms 1, 2
- Ocular abnormalities: Retinal arteriolar tortuosities, retinal hemorrhages, anterior segment dysgenesis, optic nerve hypoplasia 2, 3
- Kidney disease: Microscopic hematuria, chronic kidney disease, kidney cysts 4
- Muscular symptoms: Muscle cramps (particularly in HANAC syndrome variant) 2
- Disease onset ranges from fetal period through adulthood 2
Alport Syndrome (COL4A3/COL4A4/COL4A5 mutations):
- Kidney disease: Progressive nephropathy from hematuria → proteinuria → renal impairment → kidney failure 1
- Hearing loss: Sensorineural hearing loss 1
- Eye abnormalities: Corneal dystrophy, lenticonus, dot-and-fleck retinopathy, maculopathy 1
Key Diagnostic Features
The KDIGO 2024 guidelines recommend genetic testing for COL4A3, COL4A4, and COL4A5 as part of the evaluation for chronic kidney disease, particularly when persistent hematuria or albuminuria is present 5. COL4A disorders should be suspected in patients with familial microscopic hematuria, especially when accompanied by kidney cysts, progressive CKD, or cerebrovascular manifestations 4.
Pathophysiology
Mutations disrupt basement membrane integrity across multiple organ systems. The highly conserved C-terminal NC1 domain is critical for glomerular basement membrane integrity 4. Primary vascular defects underlie the retinopathy and cerebrovascular complications 3.
HNF1B Disorders
What They Are
HNF1B disorders are caused by mutations in the HNF1B gene (encoding hepatocyte nuclear factor-1β transcription factor) or 17q12 deletions spanning 15 genes including HNF1B 6. HNF1B is a transcription factor regulating genes expressed in kidney, pancreas, and liver 6.
Clinical Manifestations
Renal features:
- Bilateral renal cysts (though not always present) 6
- Progressive tubulointerstitial fibrosis leading to chronic kidney disease 6
- Frequent prenatal ultrasound abnormalities 6
- 44% develop CKD stages 3-4, and 21% progress to end-stage renal disease 7
- Electrolyte abnormalities: hypomagnesemia, hypokalemia 6
Extrarenal manifestations:
- Diabetes (MODY5): Present in approximately 79% of patients; 67% have clinical symptoms at diagnosis 7
- Pancreatic abnormalities: pancreatic atrophy 6
- Genital abnormalities 6
- Liver function test abnormalities 6
Diagnostic Approach
According to the 2015 KDIGO consensus, HNF1B disorders should be suspected in patients with:
- Autosomal dominant inheritance of CKD with bland urinary sediment and minimal proteinuria 6
- Prenatal ultrasound findings or childhood presentation 6
- Diabetes with renal cysts or renal disease 7
- Extrarenal manifestations (genital abnormalities, pancreatic disease) 6
Genetic testing for HNF1B is well-established and should be performed when clinical suspicion exists 6. The KDIGO 2024 guidelines specifically list HNF1B among genetic tests for CKD evaluation 5.
Genotype-Phenotype Correlations
Patients with 17q12 deletions (versus point mutations) have:
- Less severe kidney disease at diagnosis and long-term 7
- Lower rates of CKD3-4/ESRD (P < 0.0003) 7
- Leaner body habitus 7
- More frequent insulin requirement 7
Management Considerations
- Children at risk should be referred to pediatric nephrology for early management 6
- Diabetes management: Although 29 of 51 patients showed responsiveness to sulfonylureas/repaglinide, 79% ultimately required insulin therapy 7
- Monitor for diabetic complications: retinopathy and/or neuropathy present in 40% of patients 7
- At diabetes diagnosis, the presence of morphological and/or functional kidney disease should prompt consideration of HNF1B testing 7
Important Distinction
Not all HNF1B-related disease should be classified as ADTKD (Autosomal Dominant Tubulointerstitial Kidney Disease)—only cases where tubulointerstitial fibrosis is the leading manifestation, as many patients present with predominantly extrarenal features 6.
Common Pitfalls to Avoid
Don't dismiss familial kidney disease without genetic testing: Both COL4A and HNF1B disorders can present without classic family history due to de novo mutations (particularly HNF1B) or variable penetrance 6
Don't rely solely on kidney cysts for diagnosis: Cysts are neither pathognomonic nor always present in either disorder 6, 4
For potential kidney donors in affected families with known mutations, genetic testing is mandatory 6
Failure to identify a mutation does not exclude diagnosis, as not all pathogenic genes have been identified 6